| ￥3200 | |
| Z03948-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 49.02 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 52-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS, 200mM Arginine (pH 7.4). | ||||
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized DLL3, His, Mouse at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-DLL3 Antibody, hFc Tag with the EC50 of 2.1 ng/ml determined by ELISA. »
The purity of DLL3, His, Mouse is greater than 95% as determined by SEC-HPLC. »
DLL3, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand. It is highly expressed on the surface of Small cell lung cancer (SCLC) and other neuroendocrine tumors. And its expression promotes SCLC migration and invasion. DLL3 agents are evaluated in several ongoing clinical studies in SCLC and other neuroendocrine tumors. |
| Synonyms | Delta3; DLL3; Pudgy; SCDO1; SCDO1delta3 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
